Litcius/Paper detail

ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

Judith S. Currier, Carlee Moser, Joseph J. Eron, Kara W Chew, Davey M. Smith, Arzhang Cyrus Javan, David A. Wohl, Eric S. Daar, Michael D. Hughes, for the ACTIV-2/A5401 Study Team, Lara Hosey, Jhoanna Roa, Nilam Patel, Frontier Science, Bill Erhardt, Lorraine Waring, Diane Hessinger, Stacey Adams

2023The Journal of Infectious Diseases15 citationsDOIOpen Access PDF

Abstract

Clinical Trials Registration ClinicalTrials.gov Identifier: NCT04518410.

Topics & Concepts

Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BetacoronavirusMedicineCoronavirus InfectionsPandemicIntensive care medicineClinical trialVirologyInternal medicineOutbreakInfectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Sepsis Diagnosis and Treatment
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients | Litcius